| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Address correspondence and reprint requests to Dr. Karl Kieburtz, University of Rochester Medical Center, 1351 Mt. Hope Avenue, Suite 220, Rochester, NY 14620.
Objectives:— To determine whether chronic treatment with coenzyme Q10 or remacemide hydrochloride slows the functional decline of early Huntington’s disease (HD).
Methods:— The authors conducted a multicenter, parallel group, double-blind, 2 x 2 factorial, randomized clinical trial. Research participants with early HD (n = 347) were randomized to receive coenzyme Q10 300 mg twice daily, remacemide hydrochloride 200 mg three times daily, both, or neither treatment, and were evaluated every 4 to 5 months for a total of 30 months on assigned treatment. The prespecified primary measure of efficacy was the change in total functional capacity (TFC) between baseline and 30 months. Safety measures included the frequency of clinical adverse events.
Results:— Neither intervention significantly altered the decline in TFC. Patients treated with coenzyme Q10 showed a trend toward slowing in TFC decline (13%) over 30 months (2.40- versus 2.74-point decline, p = 0.15), as well as beneficial trends in some secondary measures. There was increased frequency of nausea, vomiting, and dizziness with remacemide and increased frequency of stomach upset with coenzyme Q10.
Conclusions:— Neither remacemide nor coenzyme Q10, at the dosages studied, produced significant slowing in functional decline in early HD.
This article has been cited by other articles:
|
|
 |
|
  D. E. Ehrnhoefer, S. L. Butland, M. A. Pouladi, and M. R. Hayden Mouse models of Huntington disease: variations on a theme Dis. Model. Mech., March 1, 2009; 2(3-4): 123 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Huntington Study Group TREND-HD Investigators Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease: The TREND-HD Study Arch Neurol, December 1, 2008; 65(12): 1582 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Constantinescu, M. P. McDermott, R. DiCenzo, E. A. de Blieck, H. C. Hyson, M. F. Beal, E. M. Bednarczyk, M. Bogdanov, L. J. Metakis, S. E. Browne, et al. A Randomized Study of the Bioavailability of Different Formulations of Coenzyme Q10 (Ubiquinone) J. Clin. Pharmacol., December 1, 2007; 47(12): 1580 - 1586. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shao and M. I. Diamond Polyglutamine diseases: emerging concepts in pathogenesis and therapy Hum. Mol. Genet., October 15, 2007; 16(R2): R115 - R123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Biglan and M. Halmagyi The eyes as a window into disease prevention Neurology, August 8, 2006; 67(3): 376 - 377. [Full Text] [PDF]
|
|
|
|
|
|
The Huntington Study Group PHAROS Investigators At Risk for Huntington Disease: The PHAROS (Prospective Huntington At Risk Observational Study) Cohort Enrolled. Arch Neurol, July 1, 2006; 63(7): 991 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A E Rosser, R A Barker, T Harrower, C Watts, M Farrington, A K Ho, R M Burnstein, D K Menon, J H Gillard, J Pickard, et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475 J. Neurol. Neurosurg. Psychiatry, December 1, 2002; 73(6): 678 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Blum, D. Gall, M.-C. Galas, P. d'Alcantara, K. Bantubungi, and S. N. Schiffmann The Adenosine A1 Receptor Agonist Adenosine Amine Congener Exerts a Neuroprotective Effect against the Development of Striatal Lesions and Motor Impairments in the 3-Nitropropionic Acid Model of Neurotoxicity J. Neurosci., October 15, 2002; 22(20): 9122 - 9133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Shults, D. Oakes, K. Kieburtz, M. F. Beal, R. Haas, S. Plumb, J. L. Juncos, J. Nutt, I. Shoulson, J. Carter, et al. Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline Arch Neurol, October 1, 2002; 59(10): 1541 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Verhagen Metman, M. J. Morris, C. Farmer, M. Gillespie, K. Mosby, J. Wuu, and T. N. Chase Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine Neurology, September 10, 2002; 59(5): 694 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Shoulson Experimental Neurotherapeutics: Leaps and Bounds Arch Neurol, May 1, 2002; 59(5): 689 - 691. [Full Text] [PDF]
|
|
|
|
|
|
J. T. Greenamyre and I. Shoulson We need something better, and we need it now: Fetal striatal transplantation in Huntington's disease? Neurology, March 12, 2002; 58(5): 675 - 676. [Full Text] [PDF]
|
|
|
|
|
|
C.W. Shults and A.H.V. Schapira A cue to queue for CoQ? Neurology, August 14, 2001; 57(3): 375 - 376. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
